In 2019, only 1 year after emicizumab approval, factor VIII represented $778 592 692 of $1 569 746 508 (50%) of total Medicaid spending on hemophilia pharmaceuticals; factor IX, $237 846 173 (15%); bypassing agents, $262 242 517 (17%); and emicizumab, $291 065 124 (19%). The gene discussed is F9; the disease is hemophilia.